NGL Fine Chem Q1 FY27: Revenue ₹139.16 Cr, PAT ₹18.40 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹139Cr
- +33.7% YoY
- −6.7% QoQ
- Net profit
- ₹18Cr
- +100% YoY
- +38.5% QoQ
- Margin
- 17%
- +6 pp YoY
- +3 pp QoQ
Guidance rank: #36 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on NGL Fine Chem Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Quarterly Revenue (Q1FY27): ₹139.16 crores. EBITDA for Q1FY27: ₹23.29 crores, up 112.21% YoY.
From NGL Fine Chem Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Quarterly Revenue (Q1FY27): ₹139.16 crores
- Year-on-Year (YoY) growth: 33.57%
- Revenue from Operations: ₹139.16 crores in Q1FY27 (vs. ₹104.19 crores in Q1FY26)
- Other Income: ₹7.43 crores in Q1FY27, up 16.91% YoY
- Total Income: ₹146.59 crores in Q1FY27, up 32.61% YoY
- Volume Outlook: Management commentary states sustained demand momentum with volumes remaining robust across product segments and geographies.
2 more points from NGL Fine Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Greenfield expansion at Tarapur:
- A larger expansion to drive the next leg of exponential growth.
- Estimated capex of ₹210 crore.
- Funded through debt and internal accrual.
- Civil construction underway, with ₹209.71 crore invested till Q1FY27.
- Commercial production expected to start from H2FY27.
- Phase II Capex:
- On schedule for commissioning during the current quarter (Q1FY27).
- Total project cost and scope remain unchanged.
- Expected to commence commercial production from H2FY27.
- Incremental capacity to support growth plans and new market opportunities.
- Completed expansion in subsidiary Macrotech:
2 more points from NGL Fine Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what NGL Fine Chem Ltd said on order book & pipeline — free account, 30 seconds.
NGL Fine Chem Ltd — Quarterly revenue & net profit
NGL Fine Chem Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 139 | 104 | +33.7% | 149 | -6.7% |
| Operating profit (EBITDA) | 23 | 11 | +109.1% | 21 | +9.5% |
| Operating margin | 17% | 11% | +6 pp | 14% | +3 pp |
| Profit before tax | 24 | 12 | +100% | 18 | +33.3% |
| Net profit (PAT) | 18 | 9 | +100% | 13 | +38.5% |
| EPS (₹) | 29.78 | 14.96 | +99.1% | 21.84 | +36.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were NGL Fine Chem Ltd Q1 FY27 results?
Quarterly Revenue (Q1FY27): ₹139.16 crores. EBITDA for Q1FY27: ₹23.29 crores, up 112.21% YoY.
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Greenfield expansion at Tarapur: - A larger expansion to drive the next leg of exponential growth.
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
